RxDoctor Payments Data

James Barnett, MD

Internal Medicine · San Angelo, TXNPI 1780676411

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Abbott at 32.5% of the total. Reporting peaked in 2019 at $85 and has fallen 72.9% since, to $23 in 2025. That places this record below the midpoint for internal medicine clinicians in TX, where the typical reported total is $270.

$147in general payments, 2019–2025

Across 5 payments — averaging $29.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$48
  • GE HealthCare$38
  • Lilly USA, LLC$23
  • Philips North America LLC$19
  • Boston Scientific$19
$142,862in research payments, 2019–2025

Across 9 payments — averaging $15,874 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pharmacyclics LLC, An Abbvie Company$143K

What the payments were for

  • Food & beverage$147100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$147 in reported general payments places this provider in the 35th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$55,342
Medicare patients
156
Services billed
477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$17,427
MyrbetriqMirabegron62$13,699
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$11,870
Levothyroxine Sodium302$2,557
Cholestyramine LightCholestyramine33$2,110
Memantine Hcl88$1,863
Atorvastatin Calcium147$1,750
Duloxetine Hcl73$1,596
Trazodone Hcl179$1,581
Sertraline Hcl211$1,534
Carvedilol83$1,359
Gabapentin150$1,357
Pantoprazole Sodium135$1,303
Furosemide182$1,239
Quetiapine Fumarate110$1,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$23$62738 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in San Angelo

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →